☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
osteoporosis
Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)
April 8, 2024
Sandoz Reports the US FDA’s Approval of Wyost and Jubbonti (Biosimilar, Denosumab)
March 6, 2024
Sandoz’s Jubbonti (biosimilar, denosumab) Receives Health Canada’s Approval for the Treatment of Osteoporosis
February 20, 2024
CinnaGen Reports Study Results of Biosimilar Teriparatide for the Treatment of Osteoporosis
August 24, 2023
Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab
May 25, 2023
Amgen Files BPCIA Complaint Against Sandoz Over Denosumab Biosimilar
May 10, 2023
Load more...
Back to Home